.png "A Director at Jazz Pharmaceuticals (NASDAQ: JAZZ) is Selling Shares")
Today, a Director at Jazz Pharmaceuticals (NASDAQ: JAZZ), Elmar Schnee, sold shares of JAZZ for $131K.
Following Elmar Schnee’s last JAZZ Sell transaction on August 14, 2017, the stock climbed by 35.9%. In addition to Elmar Schnee, 2 other JAZZ executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Jazz Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $500 million and quarterly net profit of $92.32 million. In comparison, last year the company earned revenue of $394 million and had a net profit of $106 million. JAZZ’s market cap is $10.64B and the company has a P/E ratio of 24.80. Currently, Jazz Pharmaceuticals has an average volume of 262.6K.
Based on 15 analyst ratings, the analyst consensus is Strong Buy with an average price target of $202.42, reflecting a -13.4% downside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
